OKYO Pharma Limited Patent for treating Ocular Pain and Inflammation
February 23 2021 - 01:00AM
RNS Non-Regulatory
TIDMOKYO
OKYO Pharma Limited
23 February 2021
OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated
Peptide Analogues for treating Ocular Pain and Inflammation
LONDON, 23 February 2021, OKYO Pharma Limited ("OKYO" or the
"Company"), a biotechnology company focused on the development of
novel drugs to treat inflammatory eye diseases and chronic ocular
pain, today announced that patent No. 10,899,796 entitled
"Compounds and Methods for Treating Pain" was issued by the United
States Patent and Trademark Office ("USPTO") on January 26, 2021.
This patent covers a class of bovine adrenal medulla (BAM) peptides
linked to specific lipids that demonstrate potential for treating
symptoms of neuropathic pain, ocular pain, ocular inflammation
and/or dry eye disease.
The work recited in this patent lays out the potential of this
class of lipidated BAM analogues as non-opioid analgesics for
ocular pain management without the side effects and potential abuse
associated with opioid medications. The Company originally
announced in February 2018 that it had obtained exclusive licenses
from On Target Therapeutics LLC and Tufts Medical Center,
respectively, covering this ophthalmic disease drug program. These
licenses included the rights to the intellectual property (IP)
estate covering composition-of-matter and methodology claims on
these lipid-linked analogues.
"The publication of this patent on our BAM-lipidated analogues
provides key IP protection crucial for bringing forward a candidate
from this class into the clinic," said Dr. Gary S. Jacob, CEO of
OKYO. "It is important to recognize that the novel element of these
drug candidates is the lipid anchor component of the molecule which
we believe is the 'secret sauce' in seeing a pharmacologic benefit
in the environment of the eye where tearing and other physiologic
phenomena normally work against the effectiveness of drugs due to
washout. We will be working hard to bring our lead BAM candidate
forward for filing an IND as we move through 2021."
About OKYO Pharma
OKYO Pharma Limited (LSE: OKYO) is a life sciences and
biotechnology company admitted to listing on the standard segment
of the Official List of the UK Financial Conduct Authority and to
trading on the Main Market for listed securities of the London
Stock Exchange plc. OKYO is focusing on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and chronic pain.
Enquiries:
OKYO Pharma Limited Willy Simon +44 (0)20 7495 2379
Optiva Securities Limited Robert Emmet +44 (0)20 3981 4173
For further information, please visit the Company's website at
www.okyopharma.com.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAZZGZZMZKGMZZ
(END) Dow Jones Newswires
February 23, 2021 02:00 ET (07:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Mar 2023 to Mar 2024